Alnylam Pharmaceuticals, Inc.
EXTRAHEPATIC DELIVERY
Last updated:
Abstract:
The invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs at one or more internal positions on at least one strand, optionally via a linker or carrier.
Status:
Application
Type:
Utility
Filling date:
7 May 2019
Issue date:
28 Apr 2022